AIxCrypto Holdings, Inc. (AIXC)
NASDAQ: AIXC · Real-Time Price · USD
2.370
-0.140 (-5.58%)
At close: Dec 15, 2025, 4:00 PM EST
2.490
+0.120 (5.06%)
Pre-market: Dec 16, 2025, 4:27 AM EST
Company Description
AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer.
The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors.
It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025.
The company was founded in 1996 and is based in Carlsbad, California.
AIxCrypto Holdings, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Software - Infrastructure |
| Sector | Technology |
| Employees | 4 |
Contact Details
Address: 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 United States | |
| Phone | 760 452 8111 |
| Website | qlgntx.com |
Stock Details
| Ticker Symbol | AIXC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001460702 |
| ISIN Number | US74754R3012 |
Key Executives
| Name | Position |
|---|---|
| Jiawei Wang | Co-Chief Executive Officer |
| Kevin A. Richardson II | Co-Chief Executive Officer, Chief Accounting Officer and Director |
| Robert W. Campbell Becher | President |
| Michael S. Poirier | Chief Operating Officer |
| Christopher L. Lotz | Vice President of Finance and Corporate Secretary |